Fig. 8.

In-vivo anticancer activity of DOX-PEG-PCL NPs, MUC1i-PEG-PCL NPs, and DM-PEG-PCL NPs in EAT model. The mice were administered treatments (10 mg/kg) intraperitoneally for 9 days after the cancer cells were implanted (i.m.), and the tumors were assessed on day 13. DOX-PEG-PCL NPs, MUC1i-PEG-PCL NPs, and DM-PEG-PCL NPs were given to treated mice, whereas vehicle was given to control animals. The use of 5FU as a positive control was used. A Tumor weight after various treatments. B Growth inhibition percentage and mortality after various treatments. C Average body weight after various treatments. Data are mean ± SE (n = 7) and One-way comparisons ANOVA were conducted between the control and treated groups. p -values *p < 0.05, **p < 0.01and***p < 0.01 were considered significant